Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Blast Crisis 1

Interventions

Methotrexate 6Cyclophosphamide 6ponatinib 5Cytarabine 5merphos 4Mycophenolic Acid 4blinatumomab 3Whole-Body Irradiation 3Tacrolimus 3Peripheral Blood Stem Cell Transplantation 3Cyclosporine 3venetoclax 2fludarabine phosphate 2bosutinib 2Vincristine 2Rituximab 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Idarubicin 2Etoposide 2Cladribine 2CT-P10 2Busulfan 2prednylidene 1pegfilgrastim 1nilotinib 1midostaurin 1gilteritinib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blast Crisis × midostaurin × 1 year × Clear all
NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
508 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡